TIDMTSP

RNS Number : 0274H

TruSpine Technologies PLC

25 July 2023

25 July 2023

TruSpine Technologies plc

("TruSpine" or the "Company")

Further re: FDA Update

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that, further to the announcement on 1 August 2022, the Company confirms that the FDA 510k submission for Cervi-LOK has been made to the FDA.

The FDA's decision to provide clearance normally takes up to 90 days, following which the Company will be able to commence marketing and sales of Cervi-LOK in the US, if clearance is received from the FDA.

CEO Laurence Strauss commented: "Following a challenging period for the Company, I am delighted to report further significant progress. The FDA submission for Cervi-LOK represents a major milestone for TruSpine, and, if clearance is received the prospect of sales revenue generation will be potentially transformational for the Company. I look forward to reporting back to you with further progress."

This announcement contains inside information for the purposes of the UK Market Abuse Regulation, and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

 
 TruSpine Technologies Plc                                   Tel: +44 (0)20 7118 0852 
 Laurence Strauss, Chief Executive Officer 
 
 Cairn Financial Advisers LLP (AQSE Corporate Adviser)       Tel: +44 (0)20 7213 0880 
 Liam Murray / Ludovico Lazzaretti 
 Peterhouse Capital Limited (Broker & Financial Adviser) 
                                                             Tel: +44 (0)20 7469 0930 
 Lucy Williams / Duncan Vasey 
 Novus Communications (PR and IR)                            Tel: +44 (0)20 7448 9839 
 Alan Green / Jacqueline Briscoe                              novuscomms@truspine.org

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXNKQBKKBKBDOB

(END) Dow Jones Newswires

July 25, 2023 02:00 ET (06:00 GMT)

TruSpine Technologies (AQSE:TSP)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos TruSpine Technologies.
TruSpine Technologies (AQSE:TSP)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos TruSpine Technologies.